



EXPEDITED PROCEDURE
EXAMINING GROUP 1643

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Box, AF, Assistant Commissioner for Patents, Washington, D. C. 20231 on April 27, 1999.

TOWNSEND and TOWNSEND and CREW LLP
By *Deleal Maalund*

18/B
M9/J
5/5/99
Patent
Attorney Docket No. 17634-000510

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of)
Brian R. Murphy et al.)
Serial No. 08/892,403)
Filed: July 15, 1997)
For: PRODUCTION OF)
ATTENUATED RESPIRATORY)
SYNCYTIAL VIRUS VACCINES)
FROM CLONED NUCLEOTIDE)
SEQUENCES)

Box AF
Assistant Commissioner for Patents
Washington, D.C. 20231

Examiner: B. Brumback
Group Art Unit: 1643
AMENDMENT AFTER FINAL

OK to enter
5/14/99
TECHNICAL DIVISION
99 MAY -4 PM 2:02
GROUP 160

Dear Sir:

In response to the Final Office Action mailed February 1, 1999 and in view of the Examiner Interviews conducted on March 17, 1999, March 23, 1999, and April 21, 1999, please amend the above identified application as follows:

IN THE CLAIMS:

Please amend claims 1, 63, and 64 as follows: 3

1. (Twice Amended) An isolated infectious recombinant respiratory syncytial virus (RSV) comprising a RSV genome or antigenome, a major nucleocapsid (N) protein, a nucleocapsid

1
2
3

213